Circassia
Circassia a cautionary tale for UK biotech, says Grainger
biotech IPO, Circassia, David Grainger, Medicxi, UK biotech
0 Comment
The UK biotech company is putting its huge failure in allergy treatment behind it. But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.
Circassia gives up on allergy treatments after second trial failure
allergy, AstraZeneca, Circassia, COPD, respiratory
0 Comment
UK biotech to focus on respiratory drugs after house dust mite therapy fails.
AZ strikes COPD deal with Circassia, suffers setback with blood drug
AstraZeneca, Circassia, COPD, respiratory
0 Comment
FDA rejects blood potassium drug for second time.
Circassia broadening pipeline after cat allergy setback
Biotech, cat allergy, Circassia, UK biotech
0 Comment
Chief executive Steve Harris confident company can bounce back
Circassia leads UK biotech funding success
allergies, biotech IPO, Circassia, IPO, UK biotech
0 Comment
